Latest From Achaogen Inc.
The UK National Health Service is to test the world's first ‘subscription’ payment model to tempt drug makers to develop new products for resistant infections.
Long-time deputy John Farley becomes acting director of the Office of Antimicrobial Products. Cox, who served as the director of the office for more than a decade, joins Regeneron to serve as vice president of regulatory affairs.
Lefamulin was approved in the US to treat community-acquired bacterial pneumonia, providing a needed IV and oral drug initially in the hospital setting, but new antibiotics have been a tough sell.
US FDA's approval of the TB Alliance's pretomanid regimen for highly treatment-resistant tuberculosis comes with an LPAD designation and advisory committee-requested language to limit use.
- Large Molecule
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Achaogen Inc.
- Senior Management
Blake Wise, CEO
Zeryn Sarpangal, CFO
Janet Dorling, Chief Commercial Officer
- Contact Info
Phone: (650) 800-3636
1 Tower Pl., Ste. 300
South San Francisco, CA 94080
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.